



Molecular Docking, Synthesis and Antibacterial activity of sulphadiazine drug modification and studying their PC3 by MTT

Sadiq S. Sadiq¹, Raghad Haddad², Hassan Hadi Kadhim³, Abbas K. Abbas⁴, Ruqaya K. Abbas⁵

¹ Department of Medical Lab Technique, College of Health and Medical Technology
Sawa University, Al-Muthana, Iraq. sadiq.s@sawauniversity.edu.iq

² Alkarkh university of science, Baghdad, Iraq. raghadalihaddad@gmail.com

³ Chemistry Department, College of Science, AL-Nahrain University, Jadriya, Baghdad, Iraq.
hasan.h.kadhim2@nahrainuniv.edu.iq

⁴ Muthana Agriculture Directorate, Ministry of Agriculture, Al-Muthana, Iraq.
Abbaschemist1991@gmail.com

⁵ Ibsina university for pharmacy and medical science, Baghdad, Iraq. Ruqaya.q@ibnsina.edu.iq

Abstract: In this study, we report a novel imine-amoxicillin synthesis (A1-A3) by reacts Sulfadiazine with different aldehydes such as 2-bromobenzaldehyde, 4-propoxybenzaldehyde, and 4-butoxybenzaldehyde. The derivatives (A1-A3) were characterized by spectroscopic technique, such as FT-IR and ¹H-NMR spectroscopy. All the synthesized derivatives were evaluated *in vitro* against different microorganisms such as *Bacillus subtilis*, *Streptococcus pneumonia*, *E. coli*, and *Bacillus subtilis* by zone inhibition method. The findings demonstrated that certain derivatives exhibit superior antibacterial properties in comparison to the efficacy of the original drug. The evaluation of derivative 1 as anticancer (breast cancer) by MTT assay and give a positive result after 24 h more than 48 h.


Keywords: Imine, Sulfadiazine, Schiff base, Drug.

Introduction

Over the past few decades, there has been an increase of drug-resistant human pathogenic microorganisms [1]. This can be attributed to the overuse and broad use of antimicrobial medicines, as well as erroneous diagnosis. Some of the drug-resistant microorganisms include methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant Enterococci, and azole-resistant *Candida* species [2]. The management of these infections is a significant obstacle, particularly in patients with weakened immune systems. To address this issue, it is imperative to explore novel and potent antimicrobial medicines. There are two basic techniques to achieve this: discovering an entirely novel antimicrobial pharmacophore and altering the structure of a well-known antimicrobial drug [3].

Drugs that include sulphur are often displayed. Sulfur-containing scaffolds are present in a wide variety of natural products and medicines [4], playing important functions and exhibiting various biological effects [5, 6]. For many years, sulphur has maintained its status as a small, ring-shaped atom that has been able to surpass 362 FDA-approved medications that contain sulphur, oxygen, or nitrogen [7]. This is achieved through the use of sulfonamide, sulfones, and compounds that have C-S bonds. The discussion will present recent advancements. Sulfonamides, also known as sulfanilamide's, are a significant group of manufactured antimicrobial medications that are widely used in pharmacology to treat a wide range of bacterial illnesses in both humans and animals [8].

Sulfadiazine, a sulfonamide medication, eradicates germs responsible for infections, particularly those affecting the urinary system. Antibiotics are ineffective against colds, flu, and other viral infections [9].



Sulfadiazine is a type of antibiotic known as a sulfonamide. Sulfonamides are artificial bacteriostatic antibiotics that have a broad range of effectiveness against most gram-positive and many gram-negative microorganisms. Nevertheless, numerous variations of a particular species can exhibit resistance [10-12]. Sulfonamides hinder bacterial reproduction by functioning as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolic pathway. The bacterial susceptibility is uniform across different sulfonamides, and resistance to one sulfonamide implies resistance to all. Oral absorption of most sulfonamides is efficient [13]. Parenteral delivery is challenging due to the high alkalinity and tissue irritation caused by soluble sulfonamide salts. Sulfonamides exhibit extensive distribution in all tissues [14]. Elevated concentrations are attained in pleural, peritoneal, synovial, and ocular fluids. While these medications are no longer employed for the treatment of meningitis, cerebrospinal fluid (CSF) levels are elevated in cases of meningeal infections. Pus hinders the antimicrobial activity [15].

In this study, we synthesis a new imine derivative via reaction sulfonamides with different aldehydes and characterize by FTIR and ¹H-NMR. Finally, tested the biological activity of these derivatives and evaluation the anticancer activity by MTT assay.

Materials and Methods

Materials: All chemicals that used in this study from sigma Aldrich company for chemical materials.

Methods

Synthesis of imine- sulphdiazine derivatives (A1-A3)

Dissolve (0.441 g, 1.0 mmol) of sulphdiazine in 20 ml of ethanol. Added 1.0 mole of corresponding aldehydes, such as 2-bromobenzaldehyde, 4-propoxybenzaldehyde, and 4-butoxybenzaldehyde to this solution. The resulting mixture was reflux for 4 h. The precipitates collected, and washed several times with absolute ethanol, dried under vacuum and kept [16, 17].


Investigation of the antimicrobial activity of Imine- sulphdiazine derivatives (A1-A3).

The several bacterial strains, including *Bacillus subtilis*, *Streptococcus pneumonia*, *E. coli*, and *Bacillus subtilis*, were cultivated on Muller-Hinton agar plates using sterile loop and streaking techniques, beginning with the broth culture. Subsequently, a distinct well was generated within the agar medium. A volume of 100 µl of the suitable dilution of imine- sulphdiazine compounds (A1 – A3) was supplied to each well, resulting in efficient absorption. The container was sealed tightly and placed in an incubator set at a temperature of 37 °C for the duration of the night, with the intention of examining it the following day [18].


Results and Discussion

The spectroscopic result, the appeared azomethine group in FTIR and disappeared amine group of amoxicillin drug and appeared proton of azomethine group of imine- sulphdiazine at ¹HNMR.


Imine derivative (A1): Molecular Formula: C₂₁H₂₂N₄O₃S, Color: Dark yellow powder, M.p.: 188-190 °C, Yield: 79%. FTIR (cm⁻¹): 3042 (C-H aromatic), 1651 (C=N), 1590 (C=C aromatic), 3339 (N-H). ¹H-NMR (ppm): 8.73 (s, 1H, N=CH), 7.17-8.57 (m, 8H, Ar) [19] [20].




Imine derivative (A2): Molecular Formula: C₁₇H₁₃BrN₄O₂S, Color: yellow powder, M.p.: 162-165 °C, Yield: 71%. FTIR (cm⁻¹): 3086 (C-H aromatic), 1652 (C=N), 1593 (C=C aromatic), 3340 (N-H).



¹H-NMR (ppm): 8.81 (s, 1H, N=CH), 6.97-8.07 (m, 11H, Ar), 3.66 (t, 2H, OCH₂), 1.31-1.72 (m, 5H, CH₂ and CH₃) [19, 21].



Imine derivative (A3): Molecular Formula: C₂₁H₂₂N₄O₃S, Color: yellow powder, M.p.: 173-175 °C, Yield: 76%. FTIR (cm⁻¹): 3071 (C-H aromatic), 1633 (C=N), 1590 (C=C aromatic). ¹H-NMR (ppm): 8.81 (s, 1H, N=CH), 7.17-8.04 (m, 11H, Ar), 3.99 (t, 2H, OCH₂), 0.96-1.77 (m, 7H, CH₂ and CH₃) [22].



Bioactivity: Table 1 shows the results of a screening process conducted on a new set of imine-amoxicillin compounds (A1-A3) to determine their antimicrobial or antibacterial capabilities in a laboratory setting. After examining the inhibitory zone data for *Bacillus subtilis*, *Streptococcus pneumoniae*, *E. coli*, and *Bacillus subtilis*, it is clear that most of the new Imine-amoxicillin combination showed better antibacterial effectiveness than the original amoxicillin molecule. There is a direct relationship between the concentration and the level of bioactivity. Derivative A1 had the most significant impact on *Streptococcus pneumoniae* bacteria [23]. Derivative A2 had the least impact on *E. coli* bacteria, as indicated in table 1.

Table 1: This study investigates the antibacterial properties of imine - sulphdiazine derivatives (A1-A3).

Derivative	Zone inhibition (mm)			
	<i>E. coli</i>	<i>Bacillus subtilis</i>	<i>Bacillus subtilis</i>	<i>Streptococcus pneumoniae</i>
A1	13	15	11	17
A2	9	12	15	16
A3	16	13	13	12

The biggest effect on Fungal was on *Aspergillus niger* by derivative A. The derivative A more biological activity from amoxicillin drug which that more activity from derivative C, as shown in table 2.

Table 2: The present study investigates the antifungal properties of imine-sulphdiazine derivative (A1-A3).

Derivative	Zone inhibition (mm)
------------	----------------------



	<i>Candida</i>	<i>Aspergillus niger</i>
A1	19	24
A3	15	18



Sulfadiazine functions as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase. This enzyme is necessary for the accurate processing of para-aminobenzoic acid (PABA), which is vital for the synthesis of folic acid. The restrained response is essential in these organisms for the production of folic acid [24].

The effect of derivative (A1) analyzed as shown in figure 7, after 48 h, increase concentration (PPM), decrease breast cancer viability % more than 24 h. All result that obtained shown in table 3. However, it is important to acknowledge that the impacts of sulfadiazine can vary depending on the individual cellular types involved. In cancer cells, sulfadiazine has been observed to cause oxidative stress, as evidenced by the rise in MDA levels [25]. This may potentially trigger the onset of apoptosis in cancer cells. On the other hand, in regular cells (THLE2), sulfadiazine seems to decrease MDA levels while enhancing the function of antioxidant enzymes, suggesting that it can effectively remove harmful free radicals in these cells [26].

Table 3: The IC50 rates of derivative (A1) induced breast cancer cell.

Concentration (PPM)	After 24 h		After 48 h	
	Mean	SD	Mean	SD
0	100	2.322349	100	3.932492
20	78.7895	2.241244	41.9806	3.089231
40	56.7513	3.986991	25.0377	2.342935
80	36.8906	3.170353	12.1439	1.029182
160	16.5532	2.963243	8.9348	1.868221
320	6.8795	2.656903	2.2401	0.338213

S (Kcal/mol)	RMSD (Å)
-5.6656	1.3911
Ligand Interactions Report	
Fri Apr 12 21:41:08 2024 (MOE 2015.10)	
5NQI: RNA / 5NQI	
Ligand	Receptor
N 24	N3 A 2670 (A) H-donor 3.13 -3.2
6-ring	C1' C 2649 (A) pi-H 4.49 -0.6
6-ring	O2' 5HM 2651 (A) pi-H 3.42 -2.1
Interactions	





Scheme 1: Routs of imine- sulphdiazine derivatives (A1-A3).

Conclusion

Imine derivative derivatives (A1-A3) were synthesized and characterized by FTIR and 1H-NMR. Chemical reactions between sulphdiazine drug and aldehyde derivatives began the synthesis. The antimicrobial activity of imine derivatives, against *Staphylococcus epidermidis*, *Pseudomonas aeruginosa*, and *Escherichia coli* were tested *in vitro*. The findings demonstrated that certain derivatives exhibit superior antibacterial properties in comparison to the efficacy of the original drug. In future, we will synthesize a new derivative and tested *in vitro*. The evaluation of derivative 1 as anticancer (breast cancer) by MTT assay and give a positive result.




Figure 1: FTIR of derivative A1.




Figure 2: FTIR of derivative A2.




Figure 3: FTIR of derivative A3.




Figure 4: ¹H NMR of derivative A1.




Figure 5: 1HNMR of derivative A2.




Figure 6: 1HNMR of derivative A3.





Figure 7: Effect of derivative (A) on breast cancer cell viability.

- [1] J. A. Alara and O. R. Alara, "An Overview of the Global Alarming Increase of Multiple Drug Resistant: A Major Challenge in Clinical Diagnosis," *Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)*, vol. 24, no. 3, pp. 26-42, 2024.
- [2] E. Jamrozik and M. J. Selgelid, "Drug-resistant infection: Causes, consequences, and responses," *Ethics and drug resistance: Collective responsibility for global public health*, pp. 3-18, 2020.
- [3] A. K. Mittal, R. Bhardwaj, P. Mishra, and S. K. Rajput, "Antimicrobials misuse/overuse: adverse effect, mechanism, challenges and strategies to combat resistance," *The Open Biotechnology Journal*, vol. 14, no. 1, 2020.
- [4] M. Mustafa and J.-Y. Winum, "The importance of sulfur-containing motifs in drug design and discovery," *Expert Opinion on Drug Discovery*, vol. 17, no. 5, pp. 501-512, 2022.
- [5] S. Carradori, P. Guglielmi, G. Luisi, and D. Secci, "Nitrogen-and Sulfur-Containing Heterocycles as Dual Anti-oxidant and Anti-cancer Agents," in *Handbook of Oxidative Stress in Cancer: Mechanistic Aspects*: Springer, 2022, pp. 2571-2588.
- [6] S. Carradori, P. Guglielmi, G. Luisi, and D. Secci, "Nitrogen-and Sulfur-Containing Heterocycles as Dual Anti-oxidant and Anti-cancer Agents," *Handbook of Oxidative Stress in Cancer: Mechanistic Aspects*, pp. 1-18, 2020.
- [7] B. Jia *et al.*, "Degradable biomedical elastomers: paving the future of tissue repair and regenerative medicine," *Chemical Society Reviews*, 2024.
- [8] G. Huang, T. Cierpicki, and J. Grembecka, "2-Aminobenzothiazoles in anticancer drug design and discovery," *Bioorganic chemistry*, p. 106477, 2023.
- [9] S. K. Debnath, M. Debnath, and R. Srivastava, "Opportunistic etiological agents causing lung infections: emerging need to transform lung-targeted delivery," *Heliyon*, vol. 8, no. 12, 2022.
- [10] A. Ovung and J. Bhattacharyya, "Sulfonamide drugs: Structure, antibacterial property, toxicity, and biophysical interactions," *Biophysical reviews*, vol. 13, no. 2, pp. 259-272, 2021.
- [11] M. Conde-Cid, A. Núñez-Delgado, M. J. Fernández-Sanjurjo, E. Álvarez-Rodríguez, D. Fernández-Calviño, and M. Arias-Estévez, "Tetracycline and sulfonamide antibiotics in soils: presence, fate and environmental risks," *Processes*, vol. 8, no. 11, p. 1479, 2020.



- [12] T. Meşeli *et al.*, "Design, synthesis, antibacterial activity evaluation and molecular modeling studies of new sulfonamides containing a sulfathiazole moiety," *New Journal of Chemistry*, vol. 45, no. 18, pp. 8166-8177, 2021.
- [13] M. Pervaiz *et al.*, "Synthesis and characterization of sulfonamide metal complexes as antimicrobial agents," *Journal of Molecular Structure*, vol. 1202, p. 127284, 2020.
- [14] S. K. Verma, R. Verma, F. Xue, P. K. Thakur, Y. Girish, and K. Rakesh, "Antibacterial activities of sulfonyl or sulfonamide containing heterocyclic derivatives and its structure-activity relationships (SAR) studies: A critical review," *Bioorganic Chemistry*, vol. 105, p. 104400, 2020.
- [15] W. K. Abdulsahib, S. H. Ganduh, N. D. Radia, and L. S. Jasim, "New approach for sulfadiazine toxicity management using carboxymethyl cellulose grafted acrylamide hydrogel," *International Journal of Drug Delivery Technology*, vol. 10, no. 2, pp. 259-264, 2020.
- [16] N. Elangovan, S. Sowrirajan, A. Y. A. Alzahrani, D. S. Rajendran Nair, and R. Thomas, "Fluorescent azomethine by the condensation of sulfadiazine and 4-chlorobenzaldehyde in solution: synthesis, characterization, solvent interactions, electronic structure, and biological activity prediction," *Polycyclic Aromatic Compounds*, pp. 1-22, 2023.
- [17] Z. M. Ali and R. K. Raheem Al-Shemary, "Design Synthesis spectroscopic studies and Preliminary Antibacterial Evaluation of Schiff Base derivative from sulfadiazine and cephalixin and its metal complexes," *AL-Muthanna Journal of Pure Science*, vol. 8, no. 2, 2021.
- [18] F. M. Arafa *et al.*, "Sulfadiazine analogs: anti-Toxoplasma in vitro study of sulfonamide triazoles," *Parasitology Research*, vol. 122, no. 10, pp. 2353-2365, 2023.
- [19] I. P. Ejidike, M. O. Bamigboye, D. A. Fadare, J. B. Adetunji, and J. A. Obaleye, "Antimalarial and Antimicrobial Activities of some Heteroleptic Metal (II) Complexes of Sulfadiazine-Vitamin C: Synthesis and Spectroscopic Studies," *Tanzania Journal of Science*, vol. 48, no. 4, pp. 973-984, 2022.
- [20] S. Khattak, X.-T. Qin, L.-H. Huang, Y.-Y. Xie, S.-R. Jia, and C. Zhong, "Preparation and characterization of antibacterial bacterial cellulose/chitosan hydrogels impregnated with silver sulfadiazine," *International Journal of Biological Macromolecules*, vol. 189, pp. 483-493, 2021.
- [21] N. Elangovan, S. Sowrirajan, N. Arumugam, A. I. Almansour, M. Altaf, and S. M. Mahalingam, "Synthesis, vibrational analysis, absorption and emission spectral studies, topology and molecular docking studies on sulfadiazine derivative," *ChemistrySelect*, vol. 9, no. 10, p. e202303582, 2024.
- [22] C. Bergonzi, A. Bianchera, G. Remaggi, M. C. Ossiprandi, R. Bettini, and L. Elviri, "3D printed chitosan/alginate hydrogels for the controlled release of silver sulfadiazine in wound healing applications: design, characterization and antimicrobial activity," *Micromachines*, vol. 14, no. 1, p. 137, 2023.
- [23] S. Srinithi, B. Arumugam, S.-M. Chen, S. Annamalai, and S. K. Ramaraj, "Synthesis and characterization of pyrochlore-type lanthanum cerate nanoparticles: Electrochemical determination of antibiotic drug sulfadiazine in biological and environmental samples," *Materials Chemistry and Physics*, vol. 296, p. 127244, 2023.
- [24] M. Venkatesan *et al.*, "Molecular mechanism of plasmid-borne resistance to sulfonamide antibiotics," *Nature Communications*, vol. 14, no. 1, p. 4031, 2023.
- [25] M. Gomaa *et al.*, "Sulfadiazine Exerts Potential Anticancer Effect in HepG2 and MCF7 Cells by Inhibiting TNF α , IL1b, COX-1, COX-2, 5-LOX Gene Expression: Evidence from In Vitro and Computational Studies," *Pharmaceuticals*, vol. 17, no. 2, p. 189, 2024.
- [26] Y.-M. Huang *et al.*, "Exploring the multifaceted impact of lanthanides on physiological pathways in human breast cancer cells," *Toxicology*, vol. 502, p. 153731, 2024.